Actualités

Infectious disease could fuel Eli Lilly's next growth phase.

On this episode of Stock Movers with Alexis Christoforous: - Shares of The Campbell's Company (CPB) edged higher ahead of the US market open after the canned soup maker reported adjusted earnings per share for the third quarter that beat the average analyst estimate. - Eli Lilly (LLY) shares gained in the early session following obesity drug presentations at the American Diabetes Association conference. Citi analysts say their conviction on Lilly is firmly intact, given the company's incretin portfolio is "not built around singular blockbusters." - Shares of Marvell Technology (MRVL) and Flex (FLEX) are rising in premarket trading as the companies are set to replace Pool Corp. and Campbell's in S&P 500 before the market open on June 22, S&P Dow Jones Indices says in emailed statement.

Popping onto the IBD Leaderboard and two exclusive screens, Eli Lilly stock has returned to buy range after a brief hiccup.

The benchmark US stock measures were mostly pointing higher before the opening bell Monday as invest

A late-stage trial showed retatrutide was effective in weight loss and in alleviating obesity-linked conditions.

More employers are requiring weigh-ins, app tracking and health coaching before approving GLP-1s for losing weight—or dropping coverage altogether.

Eli Lilly's (LLY) chairman and CEO Dave Ricks told German business newspaper Handelsblatt that Lilly would halve its planned investment in Germany, cutting its original 2.3 billion euro ($2.67 billion) commitment by roughly 50%. Reuters reported the announcement on June 3, 2026. The pullback lands ...

Dow Jones futures fell slightly after hours, along with S&P 500 futures and Nasdaq futures. The May jobs report is on tap before Friday's open. The stock market saw the Dow Jones jump to a record high, aided by lower oil prices and Treasury yields.

Eli Lilly stock is Thursday's IBD Stock Of The Day as the weight-loss behemoth deepens its focus on gene editing, vaccines and cancer.

Broadcom and CrowdStrike fell late on earnings. The SpaceX IPO price target and size have been set with the offering next week.

Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.

Eli Lilly (LLY) just did something worth paying attention to. With CVS Caremark announcing coverage of both Zepbound and newly approved Foundayo starting this summer, all three of the largest U.S. pharmacy benefit managers now cover Lilly’s complete obesity medicine portfolio. That’s a clean sweep ...

Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.

Shingles is no minor inconvenience. Ask anyone who has had it and they will tell you the burning, nerve-rattling pain can last for days. But what if surviving shingles was only half the battle? New research suggests the virus behind it could raise your risk of stroke and dementia years after the ...

The stock market rode a big rally in software stocks to fresh highs on Thursday despite another hot inflation report. The Nasdaq gained 0.9%. The Dow rose 25 points to post a slight gain and eke out a fresh record, too.

Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.

Today, May 28, 2026, investors piled into Snowflake after its Amazon pact and earnings beat, even as the Dow barely budged.

Small biotech firms "latch onto" AI more quickly than bigger firms, the head of ‌Chinese tech giant Tencent's healthcare division said on ‌Thursday, as more businesses embrace AI to improve efficiency. Pharmaceutical companies are also increasingly ​turning to AI to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency and slash costs as well as drug development timelines. Drugmakers including Novo Nordisk ‌and Eli Lilly have ⁠announced AI-related collaborations with technology firms.

May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some ‌of its drug lists as an additional preferred option ‌for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage ​on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.

Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.

Pharmaceutical companies have spent years targeting a common blood particle associated with heart-attack risks.

By Rishika Sadam and Sai Ishwarbharath B HYDERABAD/BENGALURU, May 27 (Reuters) - U.S. carrier American Airlines Group plans to double headcount at its India technology hub to about 800 by early next

Eli Lilly agreed to buy three vaccine developers targeting shingles, bacterial infections and Epstein-Barr Virus.

(Bloomberg) -- Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise. Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarUS Strikes Targets in Iran Even as Trump Hails Progress on DealRussia Tells US to Evacuate Its Diplomats and Citizens From KyivThese AI Gurus Are Charging Wall Street Banks $25,000 a DayPutin Signs Law on Use of Army

Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease...

After a brief cool-off last week, U.S. semiconductor and memory stocks are rallying in Tuesday morning trading, led by Micron, which traded above a $1 trillion market capitalization for the first time.

Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.

Eli Lilly announced deals to acquire three biotechnology companies, Curevo, LimmaTech Biologics, and Vaccine Company for roughly $3.8 billion in total consideration.

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs

Eli Lilly agreed to acquire three vaccine developers in deals worth up to nearly $4 billion combined, the company told The Wall Street Journal. Indianapolis-based Lilly has agreed to acquire Curevo, LimmaTech Biologics and Vaccine Co. Curevo is developing a shingles vaccine that Lilly believes could be as effective as the current standard but with reduced side effects, said Daniel Skovronsky, Lilly’s chief scientific and product officer.